PowerUp Acquisition Corp ( (PWUP) ) just unveiled an update.
Aspire Biopharma Holdings, Inc. recently entered into a Securities Purchase Agreement with Cobra Alternative Capital Strategies, LLC and Target Capital X LLC, resulting in the issuance of $3,750,000 in convertible debentures with a 20% original issue discount. The agreement, consummated on February 20, 2025, includes provisions for potential additional debentures and involves a security interest in all company assets. This move aligns with Aspire’s strategic efforts to secure funding for its operations, following its recent business combination with PowerUp Acquisition Corp., which transformed it from a shell company to an active entity, and signifies a step towards strengthening its financial position and executing its growth strategy.
More about PowerUp Acquisition Corp
Aspire Biopharma Holdings, Inc. is a biopharmaceutical company engaged in developing and marketing novel delivery mechanisms for drugs. The company focuses on innovative ‘do no harm’ drug technologies and operates in the biopharmaceutical industry.
YTD Price Performance: -46.06%
Average Trading Volume: 14,942
Technical Sentiment Consensus Rating: Strong Buy
See more insights into PWUP stock on TipRanks’ Stock Analysis page.